4 active not recruiting, 2 completed, 1 suspended. 6 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 3, Completed 2, Suspended 1 |
| Phase 2 | 3 | Active not recruiting 2, Suspended 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials Research Report on Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Yazeed Sawalha | 38 | 2021-11-16 | 2026-07-02 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Duvelisib, Nivolumab - Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | David Bond, MD | 7 | 2019-11-05 | 2024-05-02 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2018-09-18 | 2026-06-11 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2018-06-08 | 2026-10-02 |
Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, B-Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (5) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
CT-P10 (5) · Rituximab (5) · Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Vincristine (3) · deltacortene (3) · prednylidene (3) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · Azacitidine (1) · Biopsy (1) · Carboplatin (1) · Gemcitabine (1)
National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · David Bond, MD (1) · Northwestern University (1) · University of Washington (1) · Yazeed Sawalha (1)
United States (7)
Ajay Gopal (1) · Alex F Herrera (1) · David Bond, MD (1) · Elizabeth A Brem (1) · Elizabeth Budde (1) · Reem Karmali, MD (1) · Yazeed Sawalha, MD (1)
PMID 33786583, PMID 34686472, PMID 40706069
P30CA060553 (1), U10CA180888 (1), UM1CA186717 (1)